Exhibit
4.3


 


THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.5 BELOW, MAY NOT BE OFFERED,
SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY
TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.


 


WARRANT
TO PURCHASE STOCK


 


	Company:	Augmedix,
    Inc., a Delaware corporation
	 	 
	Number
    of Shares:	25,000
	 	 
	Type/Series
    of Stock:	Series
    B Preferred Stock of the Company
	 	 
	Warrant
    Price:	$1.6732
    per share
	 	 
	Issue
    Date:	August
    28, 2018
	 	 
	Expiration
    Date:	August
    28, 2028 (See also Section 1.6)


 


THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, Dignity Health (together with any successor or permitted assignee
or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase
the number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock
(the “Class”) of the above-named company (the “Company”) at the above-stated Warrant Price,
all as set forth above and as adjusted pursuant to SECTION 2 of this Warrant, subject to the provisions and upon the terms
and conditions set forth in this Warrant.


 


SECTION
1 EXERCISE.


 


1.1
Method of Exercise/Exchange. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by
delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise/Exchange in substantially
the form attached hereto as Appendix 1 and, unless Holder is exchanging this Warrant pursuant to a cashless exchange set forth
in Section 1.2 a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment
acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.


 


1.2
Cashless Exchange. In lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above,
but otherwise in accordance with the requirements of Section 1.1, Holder shall have the right to exchange this Warrant
or any portion hereof for a number of Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is
being exchanged. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed
using the following formula:


 


X
= Y(A-B)/A


 




    1


     


    

 


where:


 


X
= the number of Shares to be issued to the Holder;


 


Y
= the number of Shares with respect to which this Warrant is being exchanged (inclusive of the Shares surrendered to the Company
in satisfaction of the aggregate Warrant Price);


 


A
= the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and


 


B
= the Warrant Price.


 


1.3
Fair Market Value. If the Company’s common stock is then traded or quoted on a nationally recognized securities exchange,
inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the Class is common stock,
the fair market value of a Share shall be the closing price or last sale price of a share of common stock reported for the Business
Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise/Exchange to the Company.
If the Company’s common stock is then traded in a Trading Market and the Class is a series of the Company’s convertible
preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s
common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its
Notice of Exercise/Exchange to the Company multiplied by the number of shares of the Company’s common stock into which a
Share is then convertible. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the
Company shall determine the fair market value of a Share in its reasonable good faith judgment.


 


1.4
Delivery of Certificate and New Warrant. Promptly after Holder exercises or exchanges this Warrant in the manner set forth
in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to
Holder upon such exercise and, if this Warrant has not been fully exercised or exchanges and has not expired, a new warrant of
like tenor representing the Shares not so acquired.


 


1.5 Replacement
of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for
cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new
warrant of like tenor and amount.


 


1.6
Treatment of Warrant Upon Acquisition of Company.


 


(a)
Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license or other disposition of all or substantially all of the assets
of the Company; (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or
consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the
stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less
than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after
such merger, consolidation or reorganization; (iii) any sale or other transfer by the stockholders of the Company of shares representing
at least a majority of the Company’s then-total outstanding combined voting power.


 




    2


     


    

 


 


(b)
Treatment of Warrant in Cash/Public Acquisition. In the event of an Acquisition in which the consideration to be received
by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable
Securities (a “Cash/Public Acquisition”), and the fair market value of one Share as determined in accordance
with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public
Acquisition, and Holder has not exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant
shall automatically be deemed to be exchanged pursuant to Section 1.2 above as to all Shares effective immediately prior
to and contingent upon the consummation of a Cash/Public Acquisition. In connection with such exchange, Holder shall be deemed
to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof and the Company
shall promptly notify the Holder of the number of Shares (or such other securities) issued upon exercise or exchange. In the event
of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section 1.3 above
would be less than the Warrant Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will expire
immediately prior to the consummation of such Cash/Public Acquisition.


 


(c)
Sale Right in a Cash Acquisition. Notwithstanding the foregoing, in connection with an Acquisition in which the consideration
to be received by the Company’s stockholders is primarily cash, Holder shall have the right in lieu of the foregoing to
exchange this Warrant or any portion hereof for a lump-sum cash payment equal to the value of this Warrant, or portion hereof
as to which this Warrant is being exchanged. Any payments made by the Company to the Holder pursuant to this Warrant shall be
made without any deduction or withholding for or on account of taxes or otherwise. Thereupon, the Company shall pay to the Holder
such lump-sum cash payment equal to the product of “X” multiplied by “A,” each as determined in accordance
with Section 1.2 above.


 


(d)
Treatment of Warrant in Other Acquisitions. Upon the closing of any Acquisition other than a Cash/Public Acquisition defined
above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter
be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of
the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject
to further adjustment from time to time in accordance with the provisions of this Warrant; provided, however, that if the fair
market value of one Share as determined in accordance with Section 1.3 above in such Acquisition is greater than three
times the Warrant Price then in effect then the acquiring, surviving or successor entity may elect not to assume the obligations
of this Warrant and this Warrant shall terminate upon the consummation of such Acquisition, provided further, however, that the
acquiring, surviving or successor entity and the Company shall give the Holder notice in accordance with Section 3.3(d)
of this Warrant and reasonable opportunity to exercise or exchange this Warrant prior to the consummation of such Acquisition,
and in any event the provisions of Section 5.1(b) shall be applicable upon such expiration.


 


(e)
As used in this Warrant, “Marketable Securities” means securities meeting all of the following requirements:
(i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and
other information under the Securities Act of 1933, as amended (the “Act”) and the Exchange Act; (ii) the class and
series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder
to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market; and (iii) Holder would be able to
publicly re-sell, within six months following the closing of such Acquisition, all of the issuer’s shares and/or other securities
that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of
such Acquisition.


 




    3


     


    

 


SECTION
2 ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.


 


2.1
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the
Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each
Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property
which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If
the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the
number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased,
provided the aggregate purchase price shall remain the same. If the outstanding shares of the Class are combined or consolidated,
by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the
number of Shares shall be proportionately decreased, provided the aggregate purchase price shall remain the same.


 


2.2
Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class
are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class
and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and
series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of
such event, provided the aggregate purchase price shall remain the same and subject to further adjustment thereafter from time
to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to
successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events.


 


2.3
Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible preferred stock, in
the event that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common
stock pursuant to the provisions of the Company’s Certificate of Incorporation (the “Charter”), including,
without limitation, in connection with the Company’s initial, underwritten public offering and sale of its common stock
pursuant to an effective registration statement under the Act (the “IPO”), then from and after the date on which all
outstanding shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common
stock into which the Shares would have been converted had the Shares been outstanding on the date of such conversion, and the
Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares
of common stock into which one Share would have been converted, all subject to further adjustment thereafter from time to time
in accordance with the provisions of this Warrant.


 


2.4
Adjustments for Diluting Issuances. The Type/Series of Stock issuable upon exercise of this Warrant shall have the same
original issue price and conversion price as all other shares of the same Type/Series Stock of the Company. For the avoidance
of doubt, this means that if there is an adjustment to the conversion price of the Type/Series of Stock prior to the exercise
of this Warrant then the shares of the Type/Series of Stock (or Common Stock issuable upon conversion of such shares) shall have
the same conversion price as other outstanding shares of the same Type/Series notwithstanding that an adjustment to the conversion
price occurred prior to the exercise of this Warrant.


 




    4


     


    

 


2.5
No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be
issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant,
the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional
interest by (a) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (b) the
then-effective Warrant Price.


 


2.6
Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company,
at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant
Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from
Holder, furnish Holder with a certificate of its Chief Executive Officer or Chief Financial Officer, including computations of
such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment.


 


SECTION
3 REPRESENTATIONS AND COVENANTS OF THE COMPANY.


 


3.1
Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:


 


(a)
The initial Warrant Price referenced on the first page of this Warrant is not greater than the price per share at which shares
of the Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $41,830
of such shares were sold.


 


(b)
This Warrant is, and all Shares which may be issued upon the exercise of this Warrant, all securities, if any, issuable upon conversion
of the Shares and any warrants issued in substitution for or replacement of this Warrant shall, upon issuance, be duly authorized,
validly issued, fully paid and non-assessable, and free of any taxes, liens, charges and encumbrances except for restrictions
on transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at
all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the
Class, common stock and other securities as will be sufficient to permit the exercise in full of this Warrant and the conversion
of the Shares into common stock or such other securities.


 


(c)
The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material respects, as of the
Issue Date.


 


(d)
The Company (i) has been duly incorporated and is validly existing as a corporation in good standing under the laws of Delaware,
with full corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business
as presently conducted, and (ii) is duly qualified to do business as a foreign corporation and is in good standing under the laws
of each jurisdiction which requires such qualification, except in the case of clause (ii) above, to the extent that the failure
to be so qualified or be in good standing would not reasonably be expected to result in (i) a material adverse effect on the validity
or enforceability of this Warrant, (ii) a material adverse effect on the condition (financial or otherwise), earnings, business
or properties of the Company, or (iii) a material adverse effect on the Company’s ability to perform in any material respect
its obligations under this Warrant (any of (i), (ii) or (iii)) (a “Material Adverse Effect”).


 




    5


     


    

 


(e)
The Company has all requisite corporate power and authority, and has taken all requisite corporate action, to execute and deliver
this Warrant, sell and issue the Shares and carry out and perform all of its obligations under this Warrant, and without
limiting the foregoing, the Company hereby agrees that the Company shall all times have authorized and reserved the number of
Shares needed to provide for the exercise of the rights then represented by this Warrant. If at any time the Company does not
have a sufficient number of Shares authorized and available, then the Company shall call and hold a special meeting of its stockholders
within 60 days of that time for the sole purpose of increasing the number of authorized Shares to a sufficient number. This Warrant
constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except (i) as limited
by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors’
rights generally and (ii) as limited by equitable principles generally, including any specific performance.


 


(f)
No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any
federal, state, or local governmental authority on the part of the Company is required in connection with the consummation of
the transactions contemplated by this Warrant except for the filing of a Form D with the Securities and Exchange Commission (the
“Commission”) under the Securities Act and compliance with the securities and blue sky laws in the states and
other jurisdictions in which shares of Common Stock are offered and/or sold, which compliance will be effected in accordance with
such laws.


 


(g)
Neither the execution, delivery or performance of this Warrant by the Company nor the consummation of any of the transactions
contemplated thereby (including, without limitation, the issuance and sale by the Company of the Shares) will conflict with, result
in a breach or violation of, or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant
to, (i) the charter or by-laws of the Company, (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note
agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party or
bound or to which its or their property is subject, or (iii) any statute, law, rule, regulation, judgment, order or decree applicable
to the Company of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction
over the Company or any of its properties, except in the case of clauses (ii) and (iii) above, for any conflict, breach or violation
of, or imposition that would not, individually or in the aggregate, have a Material Adverse Effect.


 


(h)
Neither the Company nor any Person acting on its behalf, has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D promulgated under the Securities Act) in connection with the offer or sale of this Warrant.


 


(i)
Neither of the Company or any Person acting on its behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on
Section 4(a)(2) of the Securities Act or require registration of this Warrant under the Securities Act or cause this Warrant to
be integrated with prior offerings by the Company for purposes of the Securities Act.


 


3.2
Registration Rights/Investor Rights Agreement. The Company shall take such actions as are necessary to provide that the
Holder, upon exercise of this Warrant, is a party to the Company’s Investor Rights Agreement and entitled to “piggyback”
and S-3 registration rights.


 




    6


     


    

 


3.3
Notice of Certain Events. If the Company proposes at any time to:


 


(a)
declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock,
or other securities and whether or not a regular cash dividend;


 


(b)
offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class
or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);


 


(c)
effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares
of the Class;


 


(d)
effect an Acquisition or to liquidate, dissolve or wind up; or


 


(e)
effect an IPO;


 


then,
in connection with each such event, the Company shall give Holder:


 


(1)
at least seven Business Days prior written notice of the date on which a record will be taken for such dividend, distribution,
or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto)
or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above;


 


(2)
in the case of the matters referred to in (c) and (d) above at least seven Business Days prior written notice of the date when
the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to
exchange their shares for the securities or other property deliverable upon the occurrence of such event); and


 


(3)
with respect to the IPO, at least seven Business Days prior written notice of the date on which the Company proposes to file its
registration statement in connection therewith.


 


Company
will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s
accounting or reporting requirements.


 


SECTION
4 REPRESENTATIONS AND WARRANTIES OF THE HOLDER. 


 


The
Holder represents and warrants to the Company as follows:


 


4.1
Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being
acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution
within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant
or the Shares.


 


4.2
Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has received
or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with
respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities
and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable
effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.


 




    7


     


    

 


4.3
Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can
bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge
and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in
this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain
of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business
acumen and financial circumstances of such persons.


 


4.4
Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated
under the Act.


 


4.5
The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature
of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any
exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities
laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions
of Rule 144 promulgated under the Act.


 


4.6
Market Stand-off Agreement. Holder agrees that the Shares shall be subject to the Market Standoff provisions set forth
in Section 3.11 of that certain Amended and Restated Investors’ Rights Agreement dated May 2, 2018 by and among the Company
and certain investors of the Company listed on Schedule A thereto and certain stockholders of the Company listed on Schedule
B thereto, as may be amended, provided that Holder shall not be bound by any amendment that affects Holder’s rights
under the Loan Agreement or affects it in a manner that is different from other holders under such agreement.


 


4.7
No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant
and, except as expressly set forth in this Warrant, will not be considered a stockholder for any purpose until the exercise of
this Warrant.


 


SECTION
5 MISCELLANEOUS.


 


5.1
(a) Term and Automatic Conversion Upon Expiration. Subject to the provisions of Section 1.6 above, this Warrant
is exercisable in whole or in part at any time and from time to time on or before 6:00 P.M. Pacific time, on the Expiration Date
and shall be void thereafter.


 


(b)
Automatic Cashless Exchange upon Expiration. In the event that, upon the Expiration Date, the fair market value of one
Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater
than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exchanged
pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised,
and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued
upon such exchange to Holder.


 




    8


     


    

 


5.2
Legends. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall
be imprinted with a legend in substantially the following form:


 


THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO
DIGNITY HEALTH DATED AUGUST 28, 2018, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER
SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM
SUCH REGISTRATION.


 


THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN
THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS’ RIGHTS AGREEMENT, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL
OFFICE OF ISSUER.


 


5.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole
or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company,
as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer
is to any affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in
Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no
material question as to the availability of Rule 144 promulgated under the Act.


 


5.4
No Impairment; Further Assurances. The Company will not, by amendment of its Charter or through any reorganization, transfer
of assets, consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms to be observed or performed by it hereunder, but will at all times in good faith
assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may reasonably be requested
by Holder in order to protect the exercise privilege of Holder against dilution or other impairment, consistent with the tenor
and purpose of this Warrant. If the provisions of the Company’s Certificate of Incorporation defining the economic rights
granted to holders of the Class of Preferred Stock are restated, amended, modified, waived or otherwise affected in any manner
adverse to the Holder, without the Holder’s prior written consent, then the Holder may elect, in its sole and absolute discretion,
not to be bound by such adverse action, and the amended, modified, or waived provision of the Company’s Certificate of Incorporation
shall not apply to Holder, with regard to the Preferred Stock, or any other rights granted pursuant to this Warrant (the “Holder
Election”). The Holder Election shall only apply to Holder’s economic rights and shall not apply to any voting
or governance rights that may be held by Holder. For the avoidance of doubt, the Holder Election shall also not confer upon Holder
any additional voting and/or governance rights regardless of any modifications to the Company’s Certificate of Incorporation
that are necessary to satisfy the requirements of this Section 5.4. The Company will not increase the par value
of any Shares above the Warrant Price then in effect, and (ii) will take all such actions as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and non-assessable Shares upon the exercise of this Warrant.


 




    9


     


    

 


5.5
Transfer Procedure. Subject to the provisions of Section 5.3 and upon providing the Company with written notice,
Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable
directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however, in connection with
any such transfer, Holder will give the Company notice of the portion of the Warrant being transferred with the name, address
and taxpayer identification number of the transferee and vHolder will surrender this Warrant to the Company for reissuance to the
transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee shall agree in writing with
the Company to be bound by all of the terms and conditions of this Warrant (including the representations, warranties and covenants
set forth in Section 4 hereof).


 


5.6
Binding on Successors. This Warrant will be binding upon any entity succeeding to the Company by merger, consolidation
or acquisition of all or substantially all of the Company’s assets.


 


5.7
Taxes. The Company will pay all taxes (other than taxes based upon income) and other governmental charges that may be imposed
with respect to the issuance or delivery of the Shares, other than any tax or other charge imposed in connection with any transfer
involved in the issue and delivery of the Shares in a name other than that of the Holder.


 


5.8
Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed
delivered and effective (i) when given personally, (ii) on the third Business Day after being mailed by first-class registered
or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed
in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier
fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by
the Company or such Holder from time to time in accordance with the provisions of this Section 5.5 All notices to Holder
shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:


 


Dignity
Health


Attn:
[*]


185 Berry Street, Suite 300


San
Francisco, California 94107


	 	Telephone:	[*]


 


Email
address: [*]


With
a copy (which shall not constitute notice) to:


 


Dignity
Health


Attention:
[*]


185
Berry Street, Suite 300


San
Francisco, California 94107


 


Email: [*]


 




    10


     


    

 


Notice
to the Company shall be addressed as follows until Holder receives notice of a change in address:


 


Augmedix,
Inc.


1161
Mission Street, Suite 210


San
Francisco, CA 94103


Attention:
Matteo Marchetta, Chief Financial Officer


 


With
a copy (which shall not constitute notice) to:


 


Fenwick
& West LLP


801
California St.


Mountain
View, CA 94041


Attention:
[*]


Email: [*]


 


5.9
Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement
of such change, waiver, discharge or termination is sought.


 


5.10
Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant,
the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including
reasonable attorneys’ fees.


 


5.11
Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall
constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same
extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.


 


5.12
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without
regard to conflict of law principles that would result in the application of any other than the laws of the State of Delaware.


 


5.13
Waiver of Jury Trial. AS A MATERIAL INDUCEMENT FOR EACH PARTY HERETO TO ENTER INTO THIS WARRANT, THE PARTIES HERETO HEREBY
WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING RELATED IN ANY WAY TO THIS WARRANT AND/OR ANY AND ALL OF THE OTHER DOCUMENTS
ASSOCIATED WITH THIS TRANSACTION.


 


5.14
Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning
of any provision of this Warrant.


 


5.15
Business Days. “Business Day” is any day that is not a Saturday, Sunday or a day on which banks in New York
or Arizona are closed.


 


[Signature
page follows]


 




    11


     


    

 


IN
WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives
effective as of the Issue Date written above.


 


	“COMPANY”	 
	 	 	 
	AUGMEDIX, INC., a Delaware corporation	 
	 	 	 
	By:	/s/
    Manny Krakaris	 
	Name:  
    	Manny
    Krakaris	 
	Title:
    	Chief
    Executive Officer	 
	 	 	 
	“HOLDER”	 
	 	 	 
	DIGNITY HEALTH, a California nonprofit public benefit corporation	 
	 	 	 
	By:	/s/
    Lisa Zuckerman	 
	 	Lisa
    Zuckerman	 
	 	Its:
    Senior Vice President	 


 




     


     


    

 


APPENDIX
1


 


NOTICE
OF EXERCISE/EXCHANGE


 


1.
The undersigned Holder hereby exercises its right purchase/exchange [circle one]               
shares of the Common/Series           Preferred [circle one] Stock of
Augmedix, Inc., a Delaware corporation (the “Company”) in accordance with the attached Warrant To Purchase
Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:


 


	 	☐	check
    in the amount of $ payable to order of the Company enclosed herewith
	 	 	 
	 	☐	Wire
    transfer of immediately available funds to the Company’s account
	 	 	 
	 	☐	Cashless
    Exchange pursuant to Section 1.2 of the Warrant
	 	 	 
	 	☐	Other
    [Describe] _______________________________________


 


2.
Please issue a certificate or certificates representing the Shares in the name specified below:


 


	 	 	 	 
	 	 	Holder’s
    Name	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	(Address)	 


 


3.
By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in
SECTION 4 of the Warrant to Purchase Stock as of the date hereof.


 


	 	HOLDER:	 
	 	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Title:
    	 
	 	 	 
	 	(Date):	 



 



     


     


    

 


SCHEDULE
1


 


Company
Capitalization Table